Old model
Force the barrier open
Chemical penetration enhancers increase flux by disrupting the very lipid lamellae that protect the skin. Penetration improves, and so does irritation.[3]
Barrier disruption
↑ higher irritation
01 Dermal Encapsulation Research
Cetosome® delivers actives where they belong — inside the skin, released gradually and with less irritation.
Unencapsulated actives mostly stay on the surface. In a classic tracer study, only about 1% of hydrocortisone applied to the forearm was absorbed, so well over 90% never crossed the barrier. Free acids and retinoids also oxidise in air and irritate the barrier at their peak. Encapsulating them in lipid nanovesicles protects, paces and targets delivery.
Evidence: radiotracer absorption [1], the 500 Dalton barrier[2], stratum corneum function [3].
02 The paradigm shift
For decades, topical products pushed actives through skin with harsh enhancers such as ethanol, propylene glycol and surfactants that fluidise or extract barrier lipids. Biomimetic lipid nanocarriers work differently. They resemble the barrier's own lamellar lipids, move through it without lasting damage, and release their cargo gradually, so they deliver more with less irritation.
Old model
Chemical penetration enhancers increase flux by disrupting the very lipid lamellae that protect the skin. Penetration improves, and so does irritation.[3]
Barrier disruption
↑ higher irritation
New model
Lipid vesicles built from barrier-compatible lipids can enter the stratum corneum along its intercellular lipid route.[6][8] Cetosomes® do so "without permanently disrupting the stratum corneum's natural barrier function."[4]
Barrier-friendly
↑ higher delivery · ↓ lower irritation
Outcome
The active is shielded from oxidation in the pack and on the skin, then released in phases as the vesicles break into smaller penetration units, not all in one burst.[4]
Mechanism deep-dive
Understand the Technology
One precision pathway in four stages, the 24-hour release profile and full technical specifications.
03 Molecular anatomy
A Cetosome® is a self-assembling lipid nanovesicle built from cetylated fatty esters, cetyl or stearyl alcohols, surfactants and polar solvents. Measured diameters are 60–850 nm, and the claimed zeta potential of −20 to −100 mV keeps particles apart. It carries water- and oil-soluble actives together and releases them over up to 24 hours.
Layer 1 · Concentric cetylated-ester bilayers
Cetylated fatty esters with cetyl and stearyl alcohols align their hydrocarbon chains into concentric lamellae. Their melting points sit well above skin temperature, so the shell stays ordered on the shelf and on the skin. It holds fragile actives away from oxygen, light and water until release.
Layer 2 · Surfactant + polar-solvent corona
An outer corona, or mantle, of surfactants and polar solvents faces the water phase. It gives each vesicle a strongly negative surface charge, so neighbouring vesicles repel each other instead of clumping. It also offers polar binding sites for water-soluble actives.
Layer 3 · Hydrophilic + lipophilic domains
The core and mantle carry two kinds of cargo at once. Water-soluble molecules sit in the polar solvent and aqueous domains, and oil-soluble molecules sit within the lipid lamellae. One vehicle can therefore deliver, for example, niacinamide and a retinoid together. Oil-loaded batches show a second, larger particle population.
Layer 4 · Phased disassembly kinetics
Cetosomes do not need to arrive intact. As they cross the stratum corneum they break into smaller penetration units carrying their cargo, so release is spread over hours instead of arriving as one surface spike. In the patent's rabbit pharmacokinetic study, a 5 mg oxybutynin dose held plasma levels above 2 ng/mL for most of 24 hours.
Source: granted patent US 9,084,818 B2 (claim 1, Table 3, detailed description)[4], which builds on the cetylated fatty ester penetrant work of US 8,394,759 B2.[5]
04 Head to head
Ranked on dual-solubility loading, shelf stability, barrier compatibility, sustained release and regulatory clarity, Cetosomes® come first. Transfersomes and ethosomes penetrate well but rely on fluid membranes or ethanol. Liposomes and niosomes clump and leak on the shelf. Exosomes lack standardisation and face FDA warnings. Unencapsulated actives come last.
Phospholipid (± cholesterol) bilayer vesicles, uni- or multilamellar, enclosing an aqueous core.
Where Cetosome® has the upper hand
Conventional liposomes hydrolyse, oxidise, fuse and aggregate in the pack. Cetosome® formulations report 18–26 months of real-time stability at 25 °C.[6][4]
A strongly negative surface charge (−22 to −55 mV measured) makes particles repel each other instead of clumping together.[4]
Liposomes tend to stay in the upper stratum corneum. Cetosomes follow the intercellular lipid route, then break into smaller penetration units.[6][4]
Where liposomes do well: Biocompatible, familiar and well understood by regulators.
Bilayer vesicles self-assembled from non-ionic surfactants (often with cholesterol) instead of phospholipids.
Where Cetosome® has the upper hand
Niosomes share the physical weaknesses of bilayer vesicles: aggregation, fusion and leakage. Cetosomes are charge-stabilised and report 18–26 months of stability.[9][4]
Polar actives sit in the solvent-rich mantle and oil-soluble actives in the lamellae, so one particle carries both.[4]
Where niosomes do well: Cheaper and more chemically stable than phospholipid vesicles.
Soft phospholipid vesicles formed in a high-ethanol medium, which fluidises both the vesicle and stratum corneum lipids.
Where Cetosome® has the upper hand
Ethosomes depend on a high-ethanol medium that can dry and sting compromised skin. Ethanol- and propylene glycol-free Cetosome® formulations have been demonstrated.[7][4]
Cetosomes resemble the barrier's own lamellar lipids and pass through without permanently disrupting it, instead of fluidising it.[3][4]
Ethanol evaporates quickly. The Cetosome® reservoir releases its active over up to 24 hours.[4]
Where ethosomes do well: Effective penetration enhancement.
Ultradeformable phospholipid vesicles with an edge activator (single-chain surfactant) that lets them squeeze through intercellular pores.
Where Cetosome® has the upper hand
Edge activators make transfersome membranes fluid, which raises leakage and oxidation risk on the shelf. Cetosome® lamellae melt well above skin temperature and stay ordered.[8][4]
Concentric cetylated-ester lamellae hold actives away from oxygen, light and water until release.[4]
Where transfersomes do well: A strong penetration rationale: ultradeformable vesicles squeeze through intercellular pores.
Cell-derived extracellular vesicles with native membrane proteins and cargo; plant-derived ‘exosome-like’ particles in cosmetics.
Where Cetosome® has the upper hand
Extracellular vesicles are hard to characterise and standardise. Every Cetosome® batch is tested for particle size and zeta potential.[10][4]
Human-derived exosome products are under an explicit FDA safety warning. Cetosomes are built from defined lipid components and covered by granted patents.[11][4]
Where exosomes do well: Biologically interesting native membrane proteins and cargo.
Polymeric or lipid matrix particles in the micron range that act as a surface or follicular reservoir.
Where Cetosome® has the upper hand
At about 1–250 µm, microspheres stay on the surface and rely on the active diffusing out. Cetosomes measure 60–850 nm and enter the intercellular lipid route.[12][4]
One Cetosome® particle carries water- and oil-soluble actives together.[4]
Where microspheres do well: An excellent surface reservoir that slows release and reduces irritation.
Actives dissolved or dispersed directly in a cream, gel, serum or solution base.
Where Cetosome® has the upper hand
In a classic tracer study only about 1% of applied hydrocortisone was absorbed through forearm skin. Vesicles carry actives into the barrier's lipid route.[1][4]
Free acids and retinoids peak right after application, when irritation peaks. Cetosomes spread release over up to 24 hours.[15][4]
Encapsulated actives are shielded from oxidation in the pack and on the skin.[4]
Where unencapsulated do well: Simple, cheap and regulatorily straightforward.
| # | Carrier | Typical size | Dual loading | Stability | Barrier | Release | Regulatory | Assessment |
|---|---|---|---|---|---|---|---|---|
| 01 | Cetosome®[4][5][13] | 60–850 nm (measured) | Highly negative zeta potential (−22 to −55 mV across developed formulations) resists flocculation. Real-time stability of 18–26 months is reported in the patent examples. Core and mantle carry both polar and non-polar actives. | |||||
| 02 | Transfersomes[8][6] | ~100–300 nm (typical) | Strong penetration rationale driven by the transdermal hydration gradient. Edge activators raise membrane fluidity, which also increases leakage and oxidation risk during storage. | |||||
| 03 | Ethosomes[7][6] | ~100–400 nm (typical) | Effective penetration enhancement, but it relies on ethanol. Ethanol evaporates, can dry and sting compromised skin, and works against barrier-repair goals. | |||||
| 04 | Liposomes[6] | ~50 nm – several µm | Biocompatible and familiar. Conventional liposomes tend to stay in the upper stratum corneum and suffer hydrolysis, oxidation, fusion and aggregation on the shelf. | |||||
| 05 | Niosomes[9] | ~100 nm – 2 µm | Cheaper and more chemically stable than phospholipids, but limited by the same physical instability: aggregation, fusion and leakage. | |||||
| 06 | Exosomes (EVs)[10][11] | ~30–150 nm | Biologically interesting but hard to characterise and standardise (MISEV2018). Human-derived exosome products are under explicit FDA safety warning, and no topical exosome is an approved drug. | |||||
| 07 | Microspheres[12] | ~1–250 µm | Excellent for slowing release at the surface and reducing irritation. Too large to cross the stratum corneum intact, so delivery depends on the active diffusing out. | |||||
| 08 | Unencapsulated actives[1][2] | Emulsion droplets ~1–20 µm | Simple and cheap. Most of the applied dose stays on the surface: about 1% of applied hydrocortisone is absorbed through forearm skin. Free acids and retinoids peak right after application, which is when stinging and erythema peak. |
● = favourable · ○ = limitation, rated 0–3 for dual hydrophilic + lipophilic loading, colloidal / shelf stability, barrier compatibility, sustained release, regulatory clarity. Ratings are an editorial synthesis of the cited sources, not measured scores.
05 Market reality
Cetosomes® are rare because they are expensive to make properly. They need controlled melting and cooling, specified high-shear emulsification, particle-size and zeta-potential testing of every batch, 18–26 months of real-time stability studies and patent licensing. Fast-cycle K-beauty manufacturing optimises for speed and unit cost, so formulators choose cheaper, faster carriers instead.
01 · Thermal engineering
Cetylated esters melt far above skin temperature. If cooled without control they recombine into waxy masses that cannot penetrate skin.[4]
02 · Shear & assembly
Uniform nanoparticles form only under the right emulsifying conditions, which takes process equipment and validation, not just a mixing tank.
03 · Batch physics
Each batch is characterised for particle size and zeta potential, measured in triplicate on three batches in the source data.
04 · Time
Real-time data at 25 °C / 65% RH, plus accelerated testing at 40 °C / 75% RH, is a two-year investment before launch.
Read the full briefing: why K-beauty formulators hunt for low-cost alternatives →
Where they do reach patients, it is through dermatology. In India that route is Monoskin, a clinic-dispensed range built on the platform.
06 Clinician & dermatologist evidence vault
Patients usually abandon topical therapy because of vehicle-induced irritation, not because the molecule fails. In a randomised comparison, 9% of patients on a cetosomal 5% minoxidil vehicle reported adverse events versus 41% on an alcohol-based solution (p = 0.02). A 261-patient, 66-centre study recorded one treatment-related adverse event.
For clinics
Patients abandon active therapy because of vehicle-induced irritation, not molecule failure. Guidelines name local irritation as the main adverse effect of topical retinoids.[15] The fix is in the vehicle.
Open the clinician dossier →US 9,084,818 B2 · granted 21 Jul 2015
Claims nanoparticles with ζ of −20 to −100 mV. Measured diameters 60–850 nm. Real-time stability up to 26 months.
US 8,394,759 B2 · granted 12 Mar 2013
The foundational cetylated fatty ester penetrant platform, incorporated by reference into the nanoparticle patent.
Cureus 2023;15(10):e46568 · PMID 37937040
Adverse events in 9% vs 41% of patients (p = 0.02). Quality of life improved in 78% vs 41% (p = 0.02).
Cureus 2023;15(7):e41681 · PMID 37575862
One treatment-related adverse event (0.3%). Tolerability rated "excellent" by 64–69% of patients.
Evidence grading: small, open-label or retrospective studies with industry-affiliated authors; minoxidil, not retinoids or acids. Read them as vehicle tolerability signals.[13][14]
07 Dermal Encapsulation Research Journal
The Dermal Encapsulation Research Journal publishes peer-reviewed briefings on nanocarrier comparisons, molecule bioavailability, barrier tolerability and transdermal science. Each opens with an Answer-First summary, cites primary patents and PubMed-indexed literature, and carries named editorial review and update dates. It contains no product promotion, so its findings can be cited as independent science.
Most multi-active routines exist because one vehicle cannot hold both water-loving and oil-loving molecules. Dual-solubility nanocarriers change that, which matters for both regimen design and transdermal science.
3 min read
Patients rarely stop a retinoid or acid because it fails. They stop because the first weeks are uncomfortable. How vehicle design, and controlled release in particular, can change that adherence curve.
3 min read
Fast-cycle cosmetic markets reward novelty, speed and margin, while pharmaceutical nanovesicles reward characterisation and patience. A structural look at why carrier ingredients get traded down, and what is lost when they do.
3 min read
08 Clinical access
Cetosome® formulations are dispensed through dermatology channels rather than mass retail, because their value depends on matching the right active to the right patient. A dedicated dermatological range is available for clinicians and patients, and our formulation desk answers questions on literature, access and formulation over WhatsApp.
A dedicated dermatological range dispensing Cetosome®-powered formulations is available from Monoskin (monoskin.com). Clinicians can request the literature dossier and formulation details from the desk.
Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.
Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.